Market Place
Sourcing Support
FDA Approves Venclexta, Acalabrutinib For Untreated CLL Leukemia
23 Feb 2026 //
PRESS RELEASE
Az-Backed Coalition Launches `90S-Inspired Hypertension Campaign
17 Feb 2026 //
FIERCE PHARMA
BREZTRI Shows Positive Phase III Results In Uncontrolled Asthma
13 Feb 2026 //
BUSINESSWIRE
Astrazeneca Grants $3.4M To Enhance US Patient Healthcare Access
11 Feb 2026 //
BUSINESSWIRE
AI Transforms Pharma`s Financials Beyond Drug Discovery
11 Feb 2026 //
BIOSPACE
China indicts AstraZeneca and former exec Leon Wang over data
11 Feb 2026 //
REUTERS
Astrazeneca Relaxed About Relaxin Drug`s Poor Efficacy In Ph. 2
10 Feb 2026 //
FIERCE BIOTECH
Astrazeneca`s Oral GLP-1 Scored Phase 2 Wins, But No Data Yet
10 Feb 2026 //
FIERCE BIOTECH
AstraZeneca Eyes 25+ Blockbusters by 2030
10 Feb 2026 //
FIERCE PHARMA
AstraZeneca Gets CDSCO Nod for Imfinzi in New Indication
10 Feb 2026 //
ECONOMICTIMES
BMS And Evinova Pen Global Development Partnership
09 Feb 2026 //
FIERCE BIOTECH
Pharma Expert Addresses Standardizing CMC Quality Data
06 Feb 2026 //
RAPS
The Biggest Potential Drug Launches Of 2026
06 Feb 2026 //
FIERCE PHARMA
US Government Launches Trumprx Drug Purchasing Portal
06 Feb 2026 //
FIERCE PHARMA
AstraZeneca Wins CDSCO Nod for Durvalumab in Gastric Cancer
06 Feb 2026 //
ECONOMICTIMES
Astrazeneca Rises 1% Following Historic NYSE Transfer
03 Feb 2026 //
PR NEWSWIRE
FDA Rejects Az`s Subcutaneous Version Of Lupus Drug Saphnelo
03 Feb 2026 //
FIERCE PHARMA
Daiichi Stops Internal Development Of Next-Wave ADC
02 Feb 2026 //
FIERCE BIOTECH
Astrazeneca Begins Trading On The New York Stock Exchange
02 Feb 2026 //
BUSINESSWIRE
AstraZeneca returns to China`s CSPC for $18.5B obesity dea
31 Jan 2026 //
PRESS RELEASE
Astrazeneca Vows $15B China Investment To Boost R&D Capabilities
30 Jan 2026 //
FIERCE BIOTECH
Multiply Labs Partners to Automate Cell Therapy Manufacturing
27 Jan 2026 //
BUSINESSWIRE
AstraZeneca keeps UK Research Site on Pause, But Options Open
27 Jan 2026 //
FIERCE BIOTECH
Daiichi Sankyo Navigates Complexity Of Success
26 Jan 2026 //
FIERCE PHARMA
AstraZeneca keeps UK research site on pause, but options open
26 Jan 2026 //
FIERCE BIOTECH
AstraZeneca to delist from Nasdaq, join NYSE in February
20 Jan 2026 //
REUTERS
ENHERTU + Pertuzumab EU Filing Validated for HER2+ Breast Cancer
19 Jan 2026 //
BUSINESSWIRE
ENHERTU Plus Pertuzumab EU Type II Variation Validated
19 Jan 2026 //
BUSINESSWIRE
AstraZeneca Acquires China Rights to GPC3 Armored CAR-T Therapy
18 Jan 2026 //
PR NEWSWIRE
FDA Proposes Febrile Seizure Warnings on Flu Shot Labels
17 Jan 2026 //
FIERCE PHARMA
AZ`s $80B Revenue Target `Very Much Within Reach,` CFO Says
14 Jan 2026 //
FIERCE PHARMA
Barnardo & Astrazeneca Partner On Young Health Programme For UK
13 Jan 2026 //
PHARMIWEB
DATROWAY Ph 3 TROPION-Lung17 Trial Initiated in NSCLC Cancer
13 Jan 2026 //
BUSINESSWIRE
AstraZeneca to acquire Modella AI to Speed Oncology Drug Research
13 Jan 2026 //
PRESS RELEASE
Tempus Achieves Record Total Contract Value Exceeding $1.1 B
11 Jan 2026 //
BUSINESSWIRE
Astrazeneca Appoints Laura Colon As New President Of Spain
10 Jan 2026 //
INDPHARMAPOST
Rick R. Suarez Appointed US President Of US Biopharma Unit
09 Jan 2026 //
PHARMIWEB
Bostongene, Astrazeneca Partner To Advance Oncology Development
06 Jan 2026 //
BUSINESSWIRE
AZ Touts Phase 3 Lupus Win For Subcutaneous Saphnelo
06 Jan 2026 //
FIERCE PHARMA
Astrazeneca Elevates Vikram Chand As SVP, Head Of R&D For Japan
04 Jan 2026 //
INDPHARMAPOST
Astrazeneca`s Ph. 3 Cancer Fail Is Latest Blow To ATR Inhibitors
24 Dec 2025 //
FIERCE BIOTECH
FDA Grants ENHERTU BTD for HER2+ Early Breast Cancer
22 Dec 2025 //
BUSINESSWIRE
FDA OKs ENHERTU Breakthrough Designation for HER2+ Breast Cancer
22 Dec 2025 //
BUSINESSWIRE
Jacobio Enter Global Exclusive License Agreement with AstraZeneca
21 Dec 2025 //
PR NEWSWIRE
AZ To Pull Bleeding Reversal Agent After FDA Flags Risk Imbalance
19 Dec 2025 //
FIERCE PHARMA
Niowave Expands Supply Deal With Astrazeneca For Actinium-225
18 Dec 2025 //
PR NEWSWIRE
EU Validates DATROWAY for First-Line Metastatic Treatment
18 Dec 2025 //
BUSINESSWIRE
Astrazeneca India Granted CDSCO Approval For Datopotamab
18 Dec 2025 //
INDPHARMAPOST
Compugen Monetizes AstraZeneca Rilvegostomig Royalties Up to $90M
17 Dec 2025 //
PR NEWSWIRE
GSK`s Saphnelo EU Approved For Self-Administered Lupus Pen
16 Dec 2025 //
PHARMIWEB
FDA Approves Roche`s ENHERTU for HER2+ Metastatic Breast Cancer
16 Dec 2025 //
PR NEWSWIRE
FDA Approves AZ/Daiichi`s Enhertu in 1st-Line Breast Cancer
15 Dec 2025 //
BUSINESSWIRE
FDA Launches Probe Into Safety Of Approved Anti-RSV Antibodies
10 Dec 2025 //
BIOSPACE
Therapy Eases Side Effects for 75% of Black Breast Cancer
10 Dec 2025 //
BUSINESSWIRE
DESTINY-Ovarian01—ENHERTU Phase 3 Begins for HER2+Ovarian Cancer
09 Dec 2025 //
BUSINESSWIRE
Merck, Sanofi, AZ Shots For RSV Now Under Scrutiny By FDA
09 Dec 2025 //
FIERCE PHARMA
Pillar Bio, Astrazeneca Expand Liquid Biopsy Access In China
08 Dec 2025 //
PR NEWSWIRE
Neurimmune Expands Collaboration With Astrazeneca On NI009
04 Dec 2025 //
PR NEWSWIRE
AstraZeneca Picks Salesforce Agentforce for Life Sciences
04 Dec 2025 //
BUSINESSWIRE
AstraZeneca`s Record ASH Presence Advances Hematology
04 Dec 2025 //
BUSINESSWIRE
